[1]
|
National Board of Health, “The Cancer Register 2010 [Tal og Analyse: Cancerregisteret 2010],” National Board of Health, 2011.
|
[2]
|
A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward and D. Forman, “Global Cancer Statistics,” CA: Cancer Journal for Clinicians, Vol. 61, No. 2, 2011, pp. 69-90.
doi:10.3322/caac.20107
|
[3]
|
J. L. St Guily, I. Borget, A. Vainchtock, V. Remy and C. Takizawa, “Head and Neck Cancers in France: An Analysis of the Hospital Medical Information System (PMSI) Database,” Head & Neck Oncology, Vol. 2, 2010, p. 22.
doi:10.1186/1758-3284-2-22
|
[4]
|
E. M. Sturgis and P. M. Cinciripini, “Trends in Head and Neck Cancer Incidence in Relation to Smoking Prevalence: An Emerging Epidemic of Human Papillomavirus-Associated Cancers?” Cancer, Vol. 110, No. 7, 2007, pp. 1429-1435. doi:10.1002/cncr.22963
|
[5]
|
M. Hashibe, P. Brennan, S. C. Chuang, et al., “Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 18, No. 2, 2009, pp. 541-550.
doi:10.1158/1055-9965.EPI-08-0347
|
[6]
|
M. B. Gillespie, S. Rubinchik, B. Hoel and N. Sutkowski, “Human Papillomavirus and Oropharyngeal Cancer: What You Need to Know in 2009,” Current Treatment Options in Oncology, Vol. 10, No. 5-6, 2009, pp. 296-307.
doi:10.1007/s11864-009-0113-5
|
[7]
|
S. Marur, G. D’Souza, W. H. Westra and A. A. Forastiere, “HPV-Associated Head and Neck Cancer: A Virus-Related Cancer Epidemic,” The Lancet Oncology, Vol. 11, No. 8, 2010, pp. 781-789.
doi:10.1016/S1470-2045(10)70017-6
|
[8]
|
M. L. Gillison, G. D’Souza, W. Westra, et al., “Distinct Risk Factor Profiles for Human Papillomavirus Type 16-Positive and Human Papillomavirus Type 16-Negative Head and Neck Cancers,” Journal of the National Cancer Institute, Vol. 100, No. 6, 2008, pp. 407-420.
doi:10.1093/jnci/djn025
|
[9]
|
P. M. Weinberger, Z. Yu, B. G. Haffty, et al., “Molecular Classification Identifies a Subset of Human Papillomavirus-Associated Oropharyngeal Cancers with Favorable Prognosis,” Journal of Clinical Oncology, Vol. 24, No. 5, 2006, pp. 736-747. doi:10.1200/JCO.2004.00.3335
|
[10]
|
R. R. Laborde, V. Novakova, K. D. Olsen, J. L. Kasperbauer, E. J. Moore and D. I. Smith, “Expression Profiles of Viral Responsive Genes in Oral and Oropharyngeal Cancers,” European Journal of Cancer, Vol. 46, No. 6, 2010, pp. 1153-1158. doi:10.1016/j.ejca.2010.01.026
|
[11]
|
J. M. Lee, M. Turini, M. F. Botteman, J. M. Stephens and C. L. Pashos, “Economic Burden of Head and Neck Cancer. A Literature Review,” The European Journal of Health Economics, Vol. 5, No. 1, 2004, pp. 70-80.
doi:10.1007/s10198-003-0204-3
|
[12]
|
I. Borget, L. Abramowitz and P. Mathevet, “Economic Burden of HPV-Related Cancers in France,” Vaccine, Vol. 29, No. 32, 2011, pp. 5245-5249.
doi:10.1016/j.vaccine.2011.05.018
|
[13]
|
A. R. Kreimer, G. M. Clifford, P. Boyle and S. Franceschi, “Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 14, No. 2, 2005, pp. 467-475.
doi:10.1158/1055-9965.EPI-04-0551
|
[14]
|
M. Kruse and T. Christiansen, “Register-Based Studies of Healthcare Costs,” Scandinavian Journal of Public Health, Vol. 39, Supplement 7, 2011, pp. 206-209.
doi:10.1177/1403494811404277
|
[15]
|
H. A. Glick, J. A. Doshi, S. S. Sonnad and D. Polsky, “Analyzing Cost. Economic Evaluation in Clinical Trials,” Oxford University Press, Oxford, 2007.
|
[16]
|
J. Lipscomb, M. Ancukiewicz, G. Parmigiani, V. Hasselblad, G. Samsa and D. B. Matchar, “Predicting the Cost of Illness: A Comparison of Alternative Models Applied to Stroke,” Medical Decision Making, Vol. 18, Supplement 2, 1998, pp. S39-S56.
doi:10.1177/0272989X9801800207
|
[17]
|
D. K. Blough, C. W. Madden and M. C. Hornbrook, “Modeling Risk Using Generalized Linear Models,” Journal of Health Economics, Vol. 18, No. 2, 1999, pp. 153-171. doi:10.1016/S0167-6296(98)00032-0
|
[18]
|
M. A. Olsen, A. M. Butler, D. M. Willers, G. A. Gross, B. H. Hamilton and V. J. Fraser, “Attributable Costs of Surgical Site Infection and Endometritis after Low Transverse Cesarean Delivery,” Infection Control and Hospital Epidemiology, Vol. 31, No. 3, 2010, pp. 276-282.
doi:10.1086/650755
|
[19]
|
Ministry of Health and Prevention, National Board of Health, “[Ministeriet for Sundhed og Forebyggelse, Sundhedsstyrelsen]: Charges 2008—instructions [Takstsystem 2008—Vejledning],” Copenhagen, 2008.
|
[20]
|
J. Olsen and M. R. Jepsen, “Human Papillomavirus Transmission and Cost-Effectiveness of Introducing Quadrivalent HPV Vaccination in Denmark,” International Journal of Technology Assessment in Health Care, Vol. 26, No. 2, 2010, pp. 183-191.
doi:10.1017/S0266462310000085
|
[21]
|
J. Olsen, T. R. Jørgensen, K. Kofoed and H. K. Larsen, “Incidence and Cost of Anal, Penile, Vaginal and Vulva Cancer in Denmark,” BMC Public Health, Vol. 12, 2012, p. 1082. doi:10.1186/1471-2458-12-1082
|
[22]
|
D. Hu and S. Goldie, “The Economic Burden of Noncervical Human Papillomavirus Disease in the United States,” American Journal of Obstetrics & Gynecology, Vol. 198, No. 5, 2008, pp. 500-507.
doi:10.1016/j.ajog.2008.03.064
|
[23]
|
A. Nasman, P. Attner, L. Hammarstedt, et al., “Incidence of Human Papillomavirus (HPV) Positive Tonsillar Carcinoma in Stockholm, Sweden: An Epidemic of Viral-Induced Carcinoma?” International Journal of Cancer, Vol. 125, No. 2, 2009, pp. 362-366.
doi:10.1002/ijc.24339
|
[24]
|
L. Hammarstedt, D. Lindquist, H. Dahlstrand, et al., “Human Papillomavirus as a Risk Factor for the Increase in Incidence of Tonsillar Cancer,” International Journal of Cancer, Vol. 119, No. 11, 2006, pp. 2620-2623.
doi:10.1002/ijc.22177
|
[25]
|
S. Syrjanen, “HPV Infections and Tonsillar Carcinoma,” Journal of Clinical Pathology, Vol. 57, No. 5, 2004, pp. 449-455. doi:10.1136/jcp.2003.008656
|